Litcius/Paper detail

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

Matthew M. Gubin, Xiuli Zhang, Heiko Schuster, Étienne Caron, Jeffrey P. Ward, Takuro Noguchi, Yulia Ivanova, Jasreet Hundal, Cora D. Arthur, Willem-Jan Krebber, Gwenn E. Mulder, Mireille Toebes, Matthew D. Vesely, Samuel S.K. Lam, Alan J. Korman, James P. Allison, Gordon J. Freeman, Arlene H. Sharpe, Erika L. Pearce, Ton N. Schumacher, Ruedi Aebersold, Hans-Georg Rammensee, Cornelis J.M. Melief, Elaine R. Mardis, William E. Gillanders, Maxim N. Artyomov, Robert D. Schreiber

2014Nature1,987 citationsDOIOpen Access PDF

Topics & Concepts

ImmunotherapyAntigenBlockadeCancer researchCytotoxic T cellCancer immunotherapyEpitopeImmune checkpointImmunologyBiologyImmunogenicityMonoclonal antibodyImmune systemCancerMedicineAntibodyReceptorIn vitroBiochemistryGeneticsCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy research
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens | Litcius